金陵药业
(000919)
| 流通市值：40.32亿 | | | 总市值：42.60亿 |
| 流通股本：5.90亿 | | | 总股本：6.24亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 810,013,922.67 | 3,281,450,554.73 | 2,220,261,162.73 | 1,510,974,167.63 |
| 营业收入 | 810,013,922.67 | 3,281,450,554.73 | 2,220,261,162.73 | 1,510,974,167.63 |
| 利息收入 | 0 | 0 | - | - |
| 已赚保费 | 0 | 0 | - | - |
| 手续费及佣金收入 | 0 | 0 | - | - |
| 二、营业总成本 | 788,644,161.76 | 3,232,853,911.51 | 2,142,170,897.07 | 1,429,289,464.88 |
| 营业成本 | 653,156,391.47 | 2,675,775,027.9 | 1,770,400,774.84 | 1,194,119,580.36 |
| 利息支出 | 0 | 0 | - | - |
| 手续费及佣金支出 | 0 | 0 | - | - |
| 退保金 | 0 | 0 | - | - |
| 赔付支出净额 | 0 | 0 | - | - |
| 提取保险合同准备金净额 | 0 | 0 | - | - |
| 保单红利支出 | 0 | 0 | - | - |
| 分保费用 | 0 | 0 | - | - |
| 税金及附加 | 4,488,460.33 | 20,920,658.32 | 14,856,726.04 | 10,006,341.15 |
| 销售费用 | 22,006,480.98 | 85,576,755.22 | 67,467,572.06 | 35,535,253.14 |
| 管理费用 | 90,715,196.32 | 361,153,458.4 | 239,296,887.95 | 161,034,906.83 |
| 研发费用 | 21,182,611.02 | 110,692,239.54 | 64,403,035.8 | 37,625,764.23 |
| 财务费用 | -2,904,978.36 | -21,264,227.87 | -14,254,099.62 | -9,032,380.83 |
| 其中:利息费用 | 922,117.21 | 2,195,885.92 | 59,542.81 | 45,411.31 |
| 其中:利息收入 | 4,451,970.23 | 24,298,098.53 | 14,730,509.21 | 9,338,732.93 |
| 加:公允价值变动收益 | -1,067,815.24 | 14,387,532.64 | 17,868,995.47 | 912,611.67 |
| 加:投资收益 | 9,392,399.03 | 39,616,814.17 | -6,751,210.62 | -12,794,085.24 |
| 净敞口套期收益 | 0 | 0 | - | - |
| 汇兑收益 | 0 | 0 | - | - |
| 资产处置收益 | -10,436.12 | 21,343,277.64 | 124,411.49 | -26,206.7 |
| 资产减值损失(新) | 0 | -92,511,196.69 | 19,683.1 | - |
| 信用减值损失(新) | -1,722,880.19 | -1,051,685.9 | -5,389,403.11 | -2,033,338.41 |
| 其他收益 | 1,567,564.36 | 12,577,850.97 | 7,439,936.25 | 4,106,355.16 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 29,528,592.75 | 42,959,236.05 | 91,402,678.24 | 71,850,039.23 |
| 加:营业外收入 | 757,290.71 | 2,694,575.71 | 1,608,332.2 | 637,629.84 |
| 减:营业外支出 | 104,609.9 | 5,647,735.43 | 626,351.31 | 352,223.24 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 30,181,273.56 | 40,006,076.33 | 92,384,659.13 | 72,135,445.83 |
| 减:所得税费用 | 5,006,368.3 | 22,052,043.16 | 20,230,217.89 | 15,867,195.22 |
| 六、净利润 | 25,174,905.26 | 17,954,033.17 | 72,154,441.24 | 56,268,250.61 |
| 持续经营净利润 | 25,174,905.26 | 17,954,033.17 | 72,154,441.24 | 56,268,250.61 |
| 终止经营净利润 | 0 | - | - | - |
| 归属于母公司股东的净利润 | 22,981,989.14 | 40,409,795.74 | 71,368,654.3 | 51,818,796.27 |
| 少数股东损益 | 2,192,916.12 | -22,455,762.57 | 785,786.94 | 4,449,454.34 |
| (一)基本每股收益 | 0.04 | 0.07 | 0.12 | 0.09 |
| (二)稀释每股收益 | 0.04 | 0.07 | 0.12 | 0.09 |
| 八、其他综合收益 | 0 | -59,087.26 | 39,230.41 | - |
| 归属于母公司股东的其他综合收益 | 0 | -14,401.88 | 39,230.41 | - |
| 九、综合收益总额 | 25,174,905.26 | 17,894,945.91 | 72,193,671.65 | 56,268,250.61 |
| 归属于母公司股东的综合收益总额 | 22,981,989.14 | 40,395,393.86 | 71,407,884.71 | 51,818,796.27 |
| 归属于少数股东的综合收益总额 | 2,192,916.12 | -22,500,447.95 | 785,786.94 | 4,449,454.34 |
| 公告日期 | 2025-04-28 | 2025-03-29 | 2024-10-29 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |